To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip), call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

chronic-rhinosinusitis-with-nasal-polyps-crswnp

Chronic Rhinosinusitis With Nasal Polyps CRSWNP

<h3 style="text-align:center;">Chronic rhinosinusitis with nasal polyps (CRSwNP):</h3>

<h3 style="text-align:center;">A chronic type 2 inflammatory disease of the nasal/paranasal sinuses of the upper airway characterized by rhinosinusitis and bilateral nasal polyps1,2</h3>

<figure class="table" style="width:100%;">
 <table class="ck-table-resized" style="background-color:#1A5D70;">
 <colgroup>
 <col style="width:100%;">
 </colgroup>
 <tbody>
 <tr>
 <td style="background-color:#1A5D70;">
 <h3 style="text-align:center;">&nbsp; Type 2 inflammation drives disease pathology in up to 87% of patients with CRSwNP4</h3></td>
 </tr>
 </tbody>
 </table>
</figure>

<figure class="table" style="width:100%;">
 <table class="ck-table-resized">
 <colgroup>
 <col style="width:100%;">
 </colgroup>
 <tbody>
 <tr>
 <td style="background-color:#1A5D70;">
 <h3 style="text-align:center;">Loss of smell may be used as a diagnostic symptom and may predict CRSwNP patients with poor long-term outcomes requiring approaches beyond the standard of care</h3></td>
 </tr>
 </tbody>
 </table>
</figure>

<figure class="table" style="width:100%;">
 <table class="ck-table-resized">
 <colgroup>
 <col style="width:100%;">
 </colgroup>
 <tbody>
 <tr>
 <td style="background-color:#1A5D70;">
 <h3 style="text-align:center;">&nbsp;&nbsp;&nbsp; Type 2 inflammation in CRSwNP is associated with loss of smell</h3></td>
 </tr>
 </tbody>
 </table>
</figure>

*Clinical consequences are listed in descending order based on patient questionnaire: “Please mark the most important items affecting your health.” †Loss of smell is included in CRSwNP diagnostic criteria in the following international guideline publications: EPOS 2020, ICAR:RS 2021, EUFOREA 2021, and EAACI 2021. CRSwNP, chronic rhinosinusitis with nasal polyps; EAACI, European Academy of Allergy and Clinical Immunology; EPOS, European Position Paper on Rhinosinusitis and Nasal Polyps; EUFOREA, European Forum for Research and Education in Allergy and Airway Diseases; ICAR:RS, International Consensus Statement on Allergy and Rhinology: Rhinosinusitis; IL, interleukin; SCS, systemic corticosteroids; SOC, standard of care. 1. Fokkens WJ, et al. Rhinology. 2020;58(suppl S29):1-464. 2. Schleimer RP. Annu Rev Pathol. 2017;12:331-357. 3. Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10(4):1086-1095.e5. 4. Stevens WW, et al. J Allergy Clin Immunol Pract. 2019;7(8):2812-2820. 5. Kato A. Allergol Int. 2015;64(2):121-130. 6. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15(1):35-50. 7. Wise SK, et al. Int Forum Allergy Rhinol. 2014;4(5):361-370. 8. Takabayashi T, et al. J Allergy Clin Immunol. 2013;132(3):584-592.e4. 9. Chalermwatanachai T, et al. Sci Rep. 2018;8(1):7926. 10. Bachert C, et al. J Allergy Clin Immunol. 2021;147(1):29- 36. 11. Orlandi RR, et al. Int Forum Allergy Rhinol. 2021;11(3):213-739. 12. Agache I, et al. Allergy. 2021;76(1):14-44. 13. Rimmer J, et al. Cochrane Database Syst Rev. 2014;(12):CD006991. 14. Bakhshaee M, et al. Iran J Otorhinolaryngol. 2016;28(85):125-134. 15. Van Zele T, et al. J Allergy Clin Immunol. 2010;125:1069-1076.e4. 16. Seys SF, et al. Allergy. 2020;75(11):2867-2878.

CHRONIC-RHINOSINUSITIS-WITH-NASAL-POLYPS-CRSWNP

RESPIRATORY

Loss of Smell Is a Key Symptom in CRSwNP

<h2>Loss of Smell Improvement in Patients With CRSwNP: Results From SINUS-24 and SINUS-52a</h2>

These materials are presented by Sanofi and Regeneron Medical for scientific exchange purposes only. Please refer to the product label for full prescribing information. Figures were reproduced with permission from the publisher. *P&lt;0.05/**P&lt;0.01/***P&lt;0.001 /****Nominal P&lt;0.0001 vs placebo. aPlease see manuscripts for full details.1–3 bEligible patients were aged ≥18 years with bilateral nasal polyps and symptoms of CRS despite INCS therapy before randomization and had received SCS in the preceding 2 years (or had a medical contraindication or intolerance to SCS) or previous sinonasal surgery. In SINUS-24, patients were randomly assigned (1:1) to dupilumab 300 mg SC q2w or to matching placebo. In SINUS-52, patients were randomly assigned (1:1:1) to dupilumab 300 mg SC q2w for 52 weeks, the same schedule for the first 24 weeks followed by dupilumab 300 mg SC q4w, or placebo. cScale 0–3: Higher scores indicate greater disease severity. dPooled data from SINUS-24 and SINUS-52. e(n=724). fOnly the 710 patients who completed an UPSIT assessment at BL were included in this analysis. gNominal.hTwo deaths occurred during the study period that were deemed unrelated to the study drug; 1 patient given placebo in SINUS-24 had suspected myocardial infarction occurring after the period of TEAEs, and 1 treated with dupilumab in SINUS-52 had intracranial hemorrhage after a fall, occurring within the period of TEAEs. These patients were not included in the safety population. iInjection site reactions cluster included injection site reaction, pain, bruising and swelling. jConjunctivitis cluster included conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation. BL, baseline; CRS, chronic rhinosinusitis; INCS, intranasal corticosteroids; LoS, loss of smell; LS, least-squares; LSMD, least-squares mean difference; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneously; SCS, systemic corticosteroids; SOC, standard of care; TEAE, treatment-emergent adverse event; UPSIT, University of Pennsylvania Smell Identification Test. 1. Bachert C, et al. Lancet. 2019;394:1638–1650. 2. Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1086-1095.e5. 3. Hopkins C, et al. Int Forum Allergy Rhinol. 2021;11:1087–1101. 4. Dupixent (dupilumab) Prescribing Information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; Tarrytown, NY: Regeneron Pharmaceuticals, Inc. 2024

<h2>Loss of Smell Improvement in Patients With CRSwNP: Real-World Dataa</h2>

These materials are presented by Sanofi and Regeneron Medical for scientific exchange purposes only. Please refer to the product label for full prescribing information.&nbsp; *P&lt;0.001/ **P&lt;0.0001. aPlease see manuscripts for full details.1–3 Note that real-world data are collected from diverse sources outside the controlled environment of a clinical trial. As such, the reliability of real-world data can be hindered by data quality issues, confounding variables, and limitations in establishing causality.4 bA phase 4 real-life, observational, retrospective, multicenter study that assessed the effectiveness and safety of dupilumab 300 mg SC q2w in patients with severe uncontrolled CRSwNP over the first year of treatment. Patients enrolled were treated between November 2020 and March 2022. cA real-world prospective observational study that included patients with CRswNP who underwent treatment with dupilumab. Patients were treated with dupilumab 300 mg SC q2w as an add-on therapy to INCS. The treatment period for this study wasnot specified in the manuscript. dAn observational, retrospective multicenter study. Patients were treated with dupilumab 300 mg SC q2w as an add-on therapy to INCS for ≥1 year and followed between February 2020 and November 2022. eData from different studies are not meant to be directly compared. Data reported are not comprehensive. fThe manuscript does not provide data on the statistical significance of the change from baseline to the specified timepoint. BL, baseline; INCS, intranasal corticosteroids; LoS, loss of smell; q2w, every 2 weeks; SC, subcutaneously; VAS, Visual Analogue Scale. 1. De Corso E, et al. Allergy. 2023;78:2669–2683. 2. Albrecht T, et al. World Allergy Organ J. 2023;16:100780. 3. Ottaviano G, et al. J Pers Med. 2023;13:234. 4. Kim HS, Kim JH. J Korean Med Sci. 2019;34(4):e28. 
 &nbsp;

Loss of Smell Improvement in Patients With CRSwNP

aNo positioning of biologics was discussed. bUncontrolled CRSwNP was defined as “patient-reported lack of control and the presence of clinically relevant sinonasal symptoms of active disease (defined as overall symptom severity, nasal obstruction, and smell).” cBecause of a lack of research evaluating control in patients with CRSwNP alone, no exact cutoff was provided for patient-reported control. Advisors recommended asking patients whether their individual symptoms were controlled or burdensome with a binary (yes/no) answer. dFor research purposes, symptoms were not considered clinically relevant/bothersome when a patient’s VAS score was ≤5 cm for a particular symptom, as a previous study showed that a VAS score of 5 cm for overall symptoms severity best distinguished between patients whose CRS symptoms affected their QOL. ePreferably evaluated by nasal endoscopy. fThere was no unanimous agreement on the length of an exacerbation, but a suggestion of 6 weeks maximum was accepted. gThe 2024 definition of treatment response emphasizes individual therapy optimization (evaluate alternative diagnosis, assess treatable traits, and consider salvage surgery or biologic switch) and provides reference values for criteria compared with the definition provided in 2023.1,2 CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; EPOS, European Position Paper on Rhinosinusitis and Nasal Polyps; EUFOREA, European Forum for Research and Education in Allergy and Airways Diseases; HCP, healthcare professional; OCS, oral corticosteroids; QOL, quality of life; VAS, visual analog scale. 1. Fokkens WJ, et al. Rhinology. 2024. doi:10.4193/Rhin23.415. 2. Fokkens WJ, et al. Rhinology. 2023;61:194–202.

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

Chronic Rhinosinusitis With Nasal Polyps CRSWNP

Latest Articles

Loss of Smell Is a Key Symptom in CRSwNP

Loss of Smell Improvement in Patients With CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP